Shots:
The 1st patient has been dosed in the P-III (IOB-013/KN-D18) trial to evaluate IO102-IO103 + pembrolizumab vs pembrolizumab alone in 300 patients with prior untreated, unresectable, or MM across the US, Australia & EU. IO will sponsor the trial & maintains global commercial rights to IO102-IO103 while Merck will supply pembrolizumab
In a P-I/II trial, the combination therapy induced tumor regression & established durable antitumor response with a manageable tolerability profile, ORR (80%), CR rate (43%), grade 3-4 AEs (13%) of patients
IO102-IO103 are the immune-modulatory vaccines targeting IDO & PD-L1. The therapy has received BTD from the US FDA for MM, based on the P-I/II trial results
Ref: Globenewswire | Image: IO Biotech
